Chimerix Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
109,976.00
234,576.00
220,334.00
232,021.00
151,520.00
186,530
Total Accounts Receivable
248.00
659.00
3,102.00
2,371.00
2,283.00
589
Other Current Assets
2,765.00
2,222.00
5,401.00
2,073.00
2,730.00
2,339
Total Current Assets
112,989.00
237,457.00
228,837.00
236,465.00
156,533.00
189,458
Net Property, Plant & Equipment
338.00
1,310.00
3,045.00
2,843.00
1,894.00
1,210
Total Investments and Advances
-
52,973.00
124,040.00
47,407.00
76,731.00
-
Other Assets
60.00
138.00
70.00
55.00
72.00
46
Total Assets
113,387.00
291,878.00
355,992.00
286,770.00
235,230.00
190,714
ST Debt & Current Portion LT Debt
5,573.00
4,296.00
-
-
-
Accounts Payable
2,214.00
5,938.00
10,458.00
3,890.00
3,812.00
Other Current Liabilities
2,420.00
6,833.00
9,721.00
6,215.00
9,384.00
Total Current Liabilities
10,207.00
17,067.00
20,179.00
10,105.00
13,196.00
Long-Term Debt
4,294.00
-
-
-
-
Other Liabilities
347.00
175.00
354.00
441.00
224.00
Total Liabilities
14,848.00
17,242.00
20,533.00
10,546.00
13,420.00
Common Equity (Total)
98,539.00
274,636.00
335,459.00
276,224.00
221,810.00
Total Shareholders' Equity
98,539.00
274,636.00
335,459.00
276,224.00
221,810.00
Total Equity
98,539.00
274,636.00
335,459.00
276,224.00
221,810.00
Liabilities & Shareholders' Equity
113,387.00
291,878.00
355,992.00
286,770.00
235,230.00

About Chimerix

View Profile
Address
2505 Meridian Parkway
Durham North Carolina 27713
United States
Employees -
Website http://www.chimerix.com
Updated 07/08/2019
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R.